The Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) issued an update to the 2015–16 recommendations regarding the use of seasonal influenza vaccines.
Annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications.
For the 2016–17 influenza season, inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccines (RIV) will be available in a trivalent formulation (RIV3). Also for this season, the ACIP recommends against the use of live attenuated influenza vaccine (LAIV4), which is administered intranasally, because of recent concerns regarding low efficacy against influenza A (H1N1)pdm09 during the 2013-–14 and 2015–16 seasons.
The virus strains included in the 2016–17 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1)-like virus, an A/Hong Kong/4801/2016 (H3N2)-like virus, and a b/Brisbane/60/2008-like virus (Victorian lineage). Quadrivalent vaccines will include an additional influenza B virus strain, a B/Phuket/3073/2013-like virus (Yamagata lineage).
The report also discusses recent new vaccine licensures:
- Fluad, a MF59-adjuvanted trivalent inactivated influenza vaccine, was licensed by the FDA in November 2015 for the immunization of persons aged ≥65 years
- A quadrivalent formulation of Flucelvax (cell culture-based inactivated influenza vaccine) was licensed by the FDA in May 2016 for the immunization of persons aged ≥4 years.
For vaccination of persons with egg allergy, the new report removes the previous recommendation that egg-allergic recipients should be observed for 30 minutes post-vaccination for signs and symptoms of an allergic reaction. Clinicians should consider seeing patients for 15 minutes post-vaccination to decrease the risk of injury in case they experience syncope. Also, it includes a recommendation that persons with a history of severe allergic reaction to egg (eg, any symptom other than hives) should be vaccinated in an inpatient or outpatient medical setting under the supervision of a clinician who can recognize and manage severe allergic conditions.
The updated recommendations generally include use of different vaccine types for various populations. No specific recommendation is made for one influenza vaccine product over another in persons whom more than one licensed, recommended product is suitable.
The full recommendations are published in the CDC’s Morbidity and Mortality Weekly Report and apply to all licensed influenza vaccines used within the Food and Drug Administration.
For more information call (800) CDC-INFO or visit CDC.gov.